HRTX (Heron Therapeutics) Institutional Ownership: 88.08% (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HRTX Heron Therapeutics Inc HRTX
47 GF Score
Price $0.45
GF Value $1.53
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Heron Therapeutics Institutional Ownership?

Heron Therapeutics HRTX +0.70% 47 Institutional Ownership is 88.08% as of Jul. 15, 2026. GuruFocus rates HRTX with a GF Score™ of 47/100 and a GF Value™ of $1.53 (Possible Value Trap). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Heron Therapeutics's institutional ownership is 88.08%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Heron Therapeutics's Insider Ownership is 1.99%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Heron Therapeutics's Float Percentage Of Total Shares Outstanding is 78.45%.

Heron Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Heron Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heron Therapeutics Institutional Ownership Chart

Heron Therapeutics Historical Data

The historical data trend for Heron Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 22.69 22.77 22.92 22.60 22.33 22.39 22.13 21.35 20.95 20.95
HRTX
47GF Score
Heron Therapeutics Inc HRTX
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Heron Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 88.08% mean?
Heron Therapeutics (HRTX) has a Institutional Ownership of 88.08% as of Jul. 15, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Heron Therapeutics and its competitors.
Is Heron Therapeutics' Institutional Ownership too high?
Heron Therapeutics' current Institutional Ownership is 88.08%. Overall, Heron Therapeutics has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Heron Therapeutics' Institutional Ownership compare to ENTX and OKYO?
Heron Therapeutics' Institutional Ownership of 88.08% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Heron Therapeutics and its competitors. Heron Therapeutics's current Institutional Ownership is 88.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heron Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Heron Therapeutics (HRTX) is currently considered Possible Value Trap. The stock's GF Value™ is $1.53, compared to a current price of $0.45 — trading 70.8% below its estimated fair value. The current Institutional Ownership is 88.08%. Heron Therapeutics' overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Heron Therapeutics (HRTX), the current Institutional Ownership is 88.08% as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Heron Therapeutics (HRTX) Overvalued in 2026?

Based on GuruFocus' analysis, Heron Therapeutics stock appears to be undervalued. The current stock price of $0.45 is trading 70.8% below its estimated GF Value™ of $1.53. GuruFocus considers Heron Therapeutics to be Possible Value Trap.

Key valuation signals for HRTX:

  • Institutional Ownership: 88.08%
  • GF Value™: $1.53 vs. price of $0.45 (70.8% below fair value)
  • GF Score™: 47/100 with 4 warning signs

No single metric tells the full story. See the HRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Heron Therapeutics Business Description

Other Exchanges 0J4V:UKAXD2:Germany
Address 100 Regency Forect Drive, Suite 300, Cary, NC, USA, 27518
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
47GF Score

Get the complete analysis for HRTX

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.45
Price
$1.53
GF Value